It is made available under a CC-BY 4.0 International license .

# 1 Self-reported health, neuropsychological tests and biomarkers in fully recovered COVID-19 patients vs

# 2 patients with post-COVID cognitive symptoms: a pilot study

- 3 Short title: Cognitive symptoms in long COVID-patients vs. fully recovered COVID patients
- 4 Michael R. Lawrence,<sup>1,2</sup> Judith E. Arnetz,<sup>3\*</sup> Scott E. Counts,<sup>3,4</sup> Aiesha Ahmed,<sup>2</sup> Bengt B. Arnetz<sup>3</sup>
- <sup>5</sup> <sup>1</sup> Division of Clinical Neuropsychology, Corewell Health, Grand Rapids, Michigan, USA
- 6 <sup>2</sup> Department of Neurology, Corewell Health, Grand Rapids, Michigan, USA
- <sup>3</sup> Department of Family Medicine, College of Human Medicine, Grand Rapids, Michigan, USA
- 8 <sup>4</sup> Department of Translational Neuroscience, College of Human Medicine, Grand Rapids, MI, USA

- 10 \*Corresponding author: arnetzju@msu.edu
- 11 Author Contributions
- 12 Conceptualization: Aiesha Ahmed, Bengt B. Arnetz, Judith E. Arnetz, Michael R. Lawrence
- 13 Data Curation: Bengt B. Arnetz, Michael R. Lawrence
- 14 Formal Analysis: Bengt B. Arnetz, Judith E. Arnetz, Scott E. Counts
- 15 Funding Acquisition: Aiesha Ahmed, Bengt B. Arnetz
- 16 Investigation: Michael R. Lawrence
- 17 Methodology: Aiesha Ahmed, Bengt B. Arnetz, Judith E Arnetz, Michael R. Lawrence
- 18 Project Administration: Bengt B. Arnetz, Michael R. Lawrence
- 19 Resources: Bengt B. Arnetz, Michael R. Lawrence, Scott E. Counts
- 20 Software: Bengt B. Arnetz, Judith E. Arnetz
- 21 Supervision: Bengt B. Arnetz
- 22 Validation: Bengt B. Arnetz, Judith E. Arnetz, Michael R. Lawrence, Scott E. Counts
- 23 Visualization: Bengt B. Arnetz, Judith E. Arnetz, Michael R. Lawrence

It is made available under a CC-BY 4.0 International license .

- 24 Writing Original Draft Preparation: Aiesha Ahmed, Bengt B. Arnetz, Judith E. Arnetz, Michael R.
- 25 Lawrence
- 26 Writing Review & Editing: Aiesha Ahmed, Bengt B. Arnetz, Judith E. Arnetz, Michael R. Lawrence, Scott
- 27 E. Counts

28

It is made available under a CC-BY 4.0 International license .

### 30 Abstract

31 **Objective:** Substantial numbers of individuals who contract COVID-19 experience long-lasting cognitive 32 symptoms such as brain fog. Yet research to date has not compared these patients with healthy controls 33 with a history of laboratory-confirmed COVID-19 infection, making it difficult to understand why certain 34 COVID patients develop post-COVID cognitive symptoms while others do not. The objective of this pilot 35 study was to compare two groups of laboratory-confirmed post-COVID patients, with and without 36 cognitive symptoms, on measures of cognitive and psychological functioning, self-reported perceptions 37 of functional status and quality of life, and biomarkers of stress, inflammation, and neuroplasticity. 38 **Methods:** Using a case-control design, 17 participants were recruited from a healthcare system in 39 western Michigan, USA in 2022 through 2024. All participants were aged 25-65 and had a positive 40 polymerase chain reaction (PCR) test confirming previous COVID-19 infection. Ten participants reported 41 cognitive symptoms (long COVID group) while seven were fully recovered with no residual symptoms 42 (controls). All participants underwent an interview on their self-rated health and quality of life, a battery 43 of neurocognitive tests, and blood draw for biomarker analysis. 44 **Results:** No group differences were detected for neuropsychological test measures except for letter fluency where the long COVID group scored significantly lower (p<.05). The long COVID group had 45 significantly lower ratings than controls on quality of life, physical health, emotional functioning, and 46 47 psychological well-being. Serum levels of nerve growth factor (NGF), a biomarker of brain plasticity, 48 were significantly lower in the long COVID group, which was significantly more likely than controls to 49 have serum levels of inflammatory marker (interleukin (IL)-10) values greater than or equal to the 50 median (p=0.015). 51 **Conclusion:** Biomarker analyses suggest possible prolonged inflammatory processes in long COVID

52 patients compared to fully recovered patients. Results of decreased neuroplastic functioning give

53 credence to patients' reports of post-COVID changes in brain function.

It is made available under a CC-BY 4.0 International license .

#### 54 Introduction

55	Post COVID conditions (PCC), or long COVID, is a clinical syndrome characterized by symptoms of COVID-
56	19 that extend well beyond the initial recovery period [1]. The clinical diagnosis, termed post-acute
57	sequela of COVID-19 (PASC), was officially defined and assigned in the International Classification of
58	Diseases (ICD) - 10 in October of 2021. However, a widely accepted case definition and associated
59	symptom timeframe is still under development [2]. Research suggests that approximately 30% of
60	individuals who contract COVID-19 will go on to develop a post COVID-19 condition and experience long-
61	lasting symptoms [3]. Although symptoms are often diverse, many patients experience persistent
62	cognitive complaints, including poor memory and "brain fog" [1,4]. To date, four years after the onset of
63	the COVID-19 pandemic, cognitive symptoms continue to plague a substantial proportion of individuals
64	who have experienced the viral infection [5].
65	
66	A large survey of U.S. adults conducted during a six-month period in 2021-2022 found that 46% of those
67	with PCC reported either brain fog or impaired memory, which was associated with a decreased
68	likelihood of working full-time [6]. Another U.S. survey of nearly 15,000 adults with prior COVID-19
69	infection found that 57% of individuals with PCC experienced significantly more cognitive symptoms at

70 least daily compared to those without PCC [7]. The most commonly reported cognitive disturbances

71 involved attention, executive functioning and memory, with brain fog or processing speed deficits

72 reported in 40-60% of patients with long COVID [8]. Brain fog, or COVID fog [9] is often accompanied by

fatigue, anxiety, and depressive symptoms similar to those seen in chronic fatigue syndrome [10]. Post-

74 COVID cognitive symptoms are reported more frequently among individuals who had a mild initial

r5 infection [10, 11, 12] and in individuals who report prior cognitive difficulties and a diagnosis of

76 depressive disorder [13]. Individuals with an elevated psychological symptom burden as part of their

It is made available under a CC-BY 4.0 International license .

post COVID-19 clinical picture report more perceived cognitive difficulties in day-to-day life [14]. Post COVID cognitive symptoms have also been associated with decreased quality of life and function [15].

79

80	Notably, research to date has not shown significant objective cognitive deficits in individuals with
81	cognitive complaints related to long COVID. A study of 51 adults with post-COVID cognitive symptoms
82	reported that they scored in the normal range on standardized neuropsychological measures. However,
83	that study lacked a control group [14]. The results of neuropsychological tests in 53 outpatients
84	diagnosed with COVID-19 revealed no scores in the impaired range, leading the authors to conclude that
85	objective cognitive performance was not affected by self-reported cognitive complaints [16]. One study
86	compared adults with post-COVID conditions (n=319) to healthy controls (n=109) and found no
87	significant group differences in neuropsychological test results. Healthy controls in that study had not
88	been infected with COVID-19. However, when dividing the PCC group into those with cognitive
89	complaints (n=123) and those without (n=196), they found that those with cognitive complaints scored
90	significantly worse on global cognition, learning, memory, processing speed, language, and executive
91	function [15].
92	
93	A number of studies [e.g.,17-23] have focused on biomarkers associated with post-COVID symptoms in

94 an effort to better understand PCC, improve diagnosis, and develop potential therapeutic treatments.

95 Lai et al. [21] identified interleukin (IL)-6, C-reactive protein (CRP), tumor necrosis factor alpha (TNF-

96 alpha), and neurofilament light chain (NfL) as potential diagnostic indicators of long COVID. In a Brazilian

97 cohort, Queiroz et al. [22] found that patients with long COVID exhibited higher levels of IL-17 and IL-2,

98 whereas patients with no post-COVID symptoms had higher levels of IL-4, IL-6 and IL-10. While patients

99 in that study had all been diagnosed with COVID, the authors only compared biomarkers between

100 groups and did not report on cognitive complaints. However, due to the broad array of symptoms

It is made available under a CC-BY 4.0 International license .

101 associated with PCC, as well as the varied study designs employed, it is difficult to draw any definitive 102 conclusions regarding specific biomarkers. A few studies have focused more specifically on biomarkers 103 associated with cognitive impairment [24, 25]. In a study of 710 COVID survivors, Damiano et al. [24] 104 found no cytokines or inflammatory markers associated with cognitive performance. Vrettou et al. [25] 105 studied neural biomarkers in a cohort of 65 long COVID patients and 29 age and sex-matched healthy 106 controls with no known history of COVID infection. They found that levels of glial fibrillary acidic protein 107 (GFAP), a biomarker of neural inflammation, were significantly higher among long COVID patients, but 108 were not correlated with the presence of long COVID symptoms.

109

110 In summary, the literature to date offers sparse evidence of biomarker response to post-COVID cognitive 111 complaints, and we lack standardized phenotyping for biomarker analyses [26]. Moreover, patients with 112 PCC cognitive complaints do not seem to differ from healthy controls on neurocognitive testing but did 113 score worse than PCC patients without cognitive complaints [15]. However, patients with PCC cognitive 114 complaints may also differ in terms of psychological symptoms and self-perceived health and functional 115 status [14, 25, 27]. In any event, large numbers of individuals with PCC continue to suffer from cognitive 116 symptoms that do not seem to improve with time [5]. Studies to date have compared cognitive issues 117 between COVID laboratory-positive and laboratory-negative patients [27, 28] or followed longitudinal 118 cohorts of lab-confirmed COVID patients without comparison groups [12, 13]. The lack of studies 119 involving controls with a history of laboratory-confirmed COVID-19 infection makes it difficult to 120 enhance our understanding of why certain COVID patients develop PCC cognitive symptoms while 121 others do not. To address these gaps in the literature, the aim of the present pilot study was to compare 122 two groups of laboratory confirmed post-COVID patients, with and without cognitive symptoms, on 123 measures of cognitive and psychological functioning, self-reported perceptions of functional status and 124 quality of life, and biomarkers of stress, inflammation, and neuroplasticity.

It is made available under a CC-BY 4.0 International license .

#### 125

#### 126 Materials and Methods

- 127 Study design
- 128 This was a pilot study utilizing a case-control design.
- 129 Study participants
- 130 The sample was comprised of a total of 17 participants who had previously contracted COVID-19. All
- 131 were recruited from Corewell Health medical facilities in western Michigan, U.S. Inclusion criteria
- included being between the ages of 25-65, at least 6 months after COVID infection, and a positive
- 133 polymerase chain reaction (PCR) test confirming COVID infection. All participants were placed into one
- of two groups, a symptomatic group based upon self-report of cognitive symptoms ("long COVID"), or an
- asymptomatic control group. The asymptomatic group was fully recovered from COVID, with no residual
- 136 symptoms. Attempts were made to age and sex match the symptomatic and control group.
- 137 Data collection
- 138 Recruitment took place between March 4, 2022 and April 10, 2024. Each participant met with a study
- 139 coordinator who verbally explained the nature of the study, the research intent, and risks. Participants
- 140 then read and signed informed consent forms prior to participation. All participants underwent an
- 141 interview on their self-rated health and quality of life, a battery of neurocognitive tests, and blood draw
- 142 for biomarker analysis. Each participant was reimbursed \$75 upon completion of the approximately 2 -
- hour evaluation.
- 144 Self-report symptoms
- 145 All participants completed a brief structured interview assessing symptom complex and time
- 146 frame/course. The self-report measures focused specifically on mood, emotional functioning and quality
- 147 of life. Mood was measured using the Beck Depression Inventory [29] and Beck Anxiety Inventory [30].

#### It is made available under a CC-BY 4.0 International license .

- 148 Emotional functioning and quality of life were measured using the Short Form Health Survey SF-36 [31;
- 149 32] and the EuroQuol 5-Dimension EQ-5D [33]. Descriptions of each measure are provided in Table 1.
- 150
- 151 Table 1. Self-Report Questionnaires

Report Inventory	Description
Mood	
Beck Depression Inventory [29]	21-item self-report inventory measuring attitudes and symptoms of depression. Each item is rated on a scale from 0 to 3, with 0 indicating no symptoms and 3 indicating strong symptoms.
Beck Anxiety Inventory [30]	21-item self-report inventory measuring anxiety level and severity. Items are rated on a scale from 0 (not at all) to 3 (severely – it bothered me a lot).
Emotional Functioning/Quality of Life	
Short-Form Health Survey (SF-36) [31,32]	36-item survey measuring 8 domains of health: (1) Limitations in physical activities due to health problems; (2) Limitations in social activities due to physical or emotional problems; (3) Limitations in usual role activities due to physical health problems; (4) Bodily pain; (5) General mental health; (6) Limitations in usual role activities due to emotional problems; (7) Vitality; (8) General health perceptions.
EuroQol 5-Dimension (EQ-5D) [33]	Patient reported outcome that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 3-level severity ranking that ranges from "no problems" through "extreme problems." Also includes a 0-100 visual analogue scale to assess patient's self-rated overall health (100 = the best health you can imagine; 0 = the worst health you can imagine).

152

## 153 *Neurocognitive testing*

- 154 The interview was followed by a 90-minute neurocognitive battery assessing various aspects of
- 155 cognition including estimated premorbid functioning, attention, processing speed, verbal fluency,
- learning and memory, visual planning, and executive functioning (e.g., problem-solving, multitasking,
- 157 sustained concentration). An overview and description of the tests is provided in Table 2. All measures
- used in the current study were well known for their strong psychometric properties.
- 159 Table 2. Neuropsychological Test Measures

Test Measure	Test Description
Premorbid Intellect	
Test of Premorbid Functioning [34]	Estimate of premorbid intellect as measured by single word reading ability
Attention	

It is made available under a CC-BY 4.0 International license .

Wechsler Adult Intelligence Scale Digit Span (WAIS-IV Digit Span) [35]	Auditory attention task assessing working memory capacity; the forward memory span involves repeating sequence of numbers verbatim, while the backward memory span involves recalling numbers in reverse order. A sequencing span task is also administered in which participant orders numbers from lowest to highest.
Processing Speed	
Symbol Digit Modalities Test (SDMT) [36]	Digit-symbol transcription task involving selective attention, visual scanning, and cognitive speed; Using a reference key, participant has 90 seconds to pair specific numbers with given geometric figures. Responses can be written or given orally.
Language	
Letter fluency (COWAT) [37]	Speeded word retrieval based on letter cues; performance is based on total number of correct responses.
Semantic Fluency (Animal fluency) [37]	Rapid word generation for a semantic category; performance is based on total number of correct responses.
Visual Planning	
Rey-Osterrieth Complex Figure Test [38]	Figure copy task assessing visuo-constructional ability as well as planning/organization.
Learning and Memory	
California Verbal Learning Test (CVLT-II) [39]	Measure of learning and recall of a word list; after the initial learning phase, participants are asked to recall the list after a 20-minute delay. Indices examined include total recall (trials 1-5), free/cued short-delay recall, and free/cued long delay free recall.
Executive Functioning	
Trail Making Test [40]	Part A involves visual search and speed; participants draw a continuous line through 25 consecutively numbered circles. Part B introduces added cognitive demand of mental set-shifting; participant draws a continuous line through consecutive numbers and letters, alternating the order each time a connection is made (1-A-2-B-3-C, etc.).
Tower of London (TOL-2) [41]	Participant arranges puzzle designs using as few moves as possible. Assesses executive planning proficiency and problem-solving. Outcomes include initiation time, execution time, total time of completion, time/rule violations, and a total achievement score.

# 160

# 161 Biomarker analysis

162 Blood serum and plasma specimens were taken for biomarker analysis. All blood sampling was

163 conducted at the health system laboratory. For each participant, 30 mL blood was drawn by a licensed

164 phlebotomist, and the time of day of sample collection was recorded. All samples were frozen and

165 stored in a -80 8C freezer for later analysis. Analysis focused on biomarkers of stress (cortisol), anti-

stress or recovery (dehydroepiandrosterone sulphate, DHEA-S), inflammation (IL-6, IL-10),

167 neuroplasticity (brain-derived neurotrophic factor, BDNF, and nerve growth factor, NGF) and

168 neurodegenerative disease (neurofilament light chain, NfL). Analyte concentrations in both serum and

It is made available under a CC-BY 4.0 International license .

169	plasma samples were measured using human-specific 96 well ELISAs with the exception of NfL, which
170	was analyzed by Single Molecule Array (SIMOA) technology. The following kits were used to generate
171	data: Cortisol (Boster #EK7002, Pleasanton, CA; sensitivity > 20 ng/ml), DHEA-S (Invitrogen #EIAD HEA,
172	Carlsbad, CA; > 90.9 ng/ml), IL-6 (BioLegend #430507, San Diego, CA; > 1.6 pg/ml), IL-10 (BioLegend
173	#430607, San Diego, CA; > 2 pg/ml), BDNF (Origene #EA100205, Rockville, MD; > 2 pg/ml), NGF (AVIVA
174	#OKEH00186, San Diego, CA; > 15.6 pg/ml), and NfL (Quanterix #193186, Billerica, MA; > 1.38 pg/ml).
175	Manufacturer's instructions were followed for all assays. Duplicate samples were quantified using
176	standard curves based on calibrators of known concentration; intra-assay % CVs $\leq$ 5.2% for all assays.
177	Data analysis
178	Statistical analysis was conducted using SPSS Statistics version 29 (IBM Corp, Armonk, NY), with a two-
179	sided p value <.05 deemed statistically significant. Due to the small sample size, all comparisons
180	between the long COVID and asymptomatic control groups on self-report measures and neurocognitive
181	tests were conducted using non-parametric tests, specifically, Chi square or Fishers' exact tests for
182	discrete variables and Mann-Whitney U-tests for continuous variables. Group comparisons for
183	biomarker values utilized the natural log (Ln) for all biomarkers and were conducted using independent
184	samples T-tests. Since the study is based on relatively few participants and there are no published data
185	on recommended cut-off levels for biomarkers applicable to PCC patients, additional analyses were
186	conducted by dichotomizing the biomarkers into below the median vs equal to or above the median
187	based on aggregate data for all participants. Using these cutoffs, group comparisons were conducted to
188	examine whether the proportion of participants across the two groups above and below the median
189	differed statistically. In a final step, a pro-inflammatory index was created by summing up the absolute
190	values for IL-10 and IL6. The long COVID scores were compared with the controls using total scores as
191	well as the Ln transformed scores. The serum pro-inflammatory Index was dichotomized into less than

It is made available under a CC-BY 4.0 International license .

- the median (=5.4005 pg/mL) vs greater than or equal to the median. Fisher's exact 2-sided test was used
- 193 for these analyses, with significance set at p<.05.
- 194
- 195 Ethical Considerations
- 196 The study was approved by the Institutional Review Board at Corewell Health (IRB nr. 2020-601).
- 197
- 198 Results
- 199 Demographic characteristics of study participants are summarized and compared by group in Table 3.
- 200 The mean age was 42 years in the long COVID group and 44.32 in the controls. All but one participant

201 was female, all but two identified as White, and none identified as Hispanic. Most participants in both

- 202 groups had a high school diploma or associate degree as their highest educational degree. All seven
- 203 control group participants were employed, compared to 6 of 10 in the long COVID group. Three of the 4
- 204 unemployed reported that their unemployment was due to their post COVID condition. None of the
- 205 group differences were statistically significant.

### 206 Table 3. Demographics of long COVID (n=10) vs Controls (n=7)

Long COVID	Controls	р
42.00 (3.18)	44.32 (4.89)	ns
N (%)	N (%)	
		ns
1 (10)	0	
9 (90)	7 (100)	
		ns
0	1 (14.3)	
10 (100)	5 (71.4)	
0	1 (14.3)	
		ns
5 (50)	4 (57.1)	
2 (20)	2 (28.6)	
3 (30)	0	
0	1 (14.3)	
	Long COVID 42.00 (3.18) N (%) 1 (10) 9 (90) 0 10 (100) 0 5 (50) 2 (20) 3 (30) 0	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

It is made available under a CC-BY 4.0 International license .

		ns
6 (60)	7 (100)	
4 (40)	0	
	6 (60) 4 (40)	6 (60) 7 (100) 4 (40) 0

# SE = standard error; significance tested using Mann-Whitney U-tests and Chi square statistics

209 Self-report measures and neurocognitive tests

210 Group differences on self-report measures for emotional functioning/quality of life and mood, and on 211 objective neuropsychological tests are summarized in Table 4. On self-report measures, individuals with 212 long COVID scored significantly higher than controls, indicating a higher level of problems on the quality 213 of life measures for usual activity (2.20 vs. 1.00, p=.002) and pain/discomfort (2.20 vs. 1.17, p=.007), as 214 well as on the EuroQol 5-Dimension (EQ-5D EQ5D3L) total score (9.50 vs. 5.50, p<.001). There were no 215 significant group differences for mobility, self-care, and anxiety/depression. The long COVID group 216 scored significantly lower (mean 38.10) than the non-symptomatic group (mean 89.17) on the visual 217 analogue scale (VAS) for self-rated health, ranging from 0 (worst health you can imagine) to 100 (best health you can imagine). On the SF-36 quality of life measures, the long COVID group scored significantly 218 219 lower than the healthy controls on all eight dimensions (p<.01). Thus, those with post-COVID cognitive 220 complaints experienced greater limitations in physical and social activities due to physical and emotional 221 health problems, and reported worse bodily pain, general mental health, and lower vitality, i.e., less 222 energy and more fatigue, than controls. The long COVID group also scored significantly higher on both 223 mood measures (depression, mean 27.50 vs. 3.86, p<.001; anxiety, 21.40 vs. 4.57, p=.002) than healthy 224 controls.

Table 4. Self-report measures and Neurocognitive resting of Long COVID (II-10) vs Controls (II - 7)				
Long COVID	Controls			
mean	mean	p		
1.60	1.00	ns		
1.40	1.00	ns		
2.20	1.00	.002		
2.20	1.17	.007		
2.10	1.33	ns		
38.10	89.17	.005		
9.50	5.50	<.001		
	Long COVID mean 1.60 1.40 2.20 2.20 2.10 38.10 9.50	Long COVID         Controls           mean         mean           1.60         1.00           1.40         1.00           2.20         1.00           2.20         1.17           2.10         1.33           38.10         89.17           9.50         5.50		

Table 4. Self-report ineasures and ineurocognitive resting of Long COVID ( $n-10$ ) vs controls ( $n-7$	Table 4. Self-re	eport Measures an	d Neurocognitive	Testing of Long	g COVID (I	n=10) vs	S Controls (	n = 7
---	------------------	-------------------	------------------	-----------------	------------	----------	--------------	-------

<u>Quality of Life: SF-36</u>			
Phys Funct Raw	46.00	97.50	.003
Role Funct Phys Raw	10.00	100.00	.002
Role funct Emo Raw	9.93	100.00	<.001
Energy Fatigue Raw	17.00	70.00	<.001
Emo Well-Being Raw	48.80	82.67	.003
Social Funct Raw	21.25	93.75	<.001
Pain Raw	45.25	96.25	.003
Gen Health Raw	28.00	81.67	<.001
Mood			
Beck Depression Raw	27.50	3.86	<.001
Beck Anxiety Raw	21.40	4.57	.002
Learning and Memory: California Verbal Learning			
<u>Test (CVLT-II)</u>			
Cali Verbal 1-5 Learning Total Raw	46.30	53.43	ns
Cali Verbal 1-5 Learning Total T Score	45.70	52.29	ns
Cali Verbal Learning Trial 1 Raw	5.90	6.43	ns
Cali Verbal Learning Trial 1 Z-Score	-0.65	-0.36	ns
Cali Verbal Learning Trial 5 Raw	11.40	13.14	ns
Cali Verbal Learning Trial 5 Z-Score	-0.60	-0.07	ns
Cali Verbal Learning List B Raw	5.00	5.43	ns
Cali Verbal Learning List B Z-Score	-0.75	-0.50	ns
Cali Verbal Test 1-5 Learning Slope Raw	1.38	1.69	ns
Cali Verbal Test 1-5 Learning Slope Z-Score	-0.10	0.36	ns
Cali Verbal Test Short Delay Free Recall Raw	10.60	11.00	ns
Cali Verbal Test Short Delay Free Recall Z-Score	-0.20	-0.14	ns
Cali Verbal Test Short Delay Cued Recall Raw	11.90	11.86	ns
Cali Verbal Test Short Delay Cued Recall Z-Score	-0.15	-0.21	ns
Cali Verbal Test Long Delay Free Recall Raw	10.20	12.00	ns
Cali Verbal Test Long Delay Free Recall Z-Score	-0.45	0.07	ns
Cali Verbal Test Long Delay Cued Recall Raw	11.40	12.29	ns
Cali Verbal Test Long Delay Cued Recall Z-Score	-0.45	-0.21	ns
Cali Verbal Test Recognition Hits Raw	13.50	15.14	ns
Cali Verbal Test Recognition Hits Z Score	-1.20	-0.29	ns
Cali Verbal Test False Pos Raw	2.00	0.71	ns
Cali Verbal Test False Pos Z Score	0.10	-0.43	ns
Cali Verbal Test Recognition Discrimination Raw	2.87	3.53	ns
Cali Verbal Test Recognition Discrimination ZScore	-0.35	0.50	ns
Attention: Wechsler Adult Intelligence Scale Digit			
Snan (WAIS-IV Digit Snan)			
Wechsler Digit Forward Raw	9 70	10 14	ns
Wechsler Digit Backward Raw	5.70 7.70	6 86	ns
Reliable Digit Span Raw	9.00	0.00 8 57	ns
Wechsler Sea Span Raw	6 70	8.00	ns
Wechsler Digit Snan Scaled Score	8.63	8.00	ns
	0.05	0.71	115
Processing Speed: Symbol Digits Modality Test	43 50	EQ 42	
	43.50	50.43	ns

#### It is made available under a CC-BY 4.0 International license .

Symbol Digit Mod Z Score	-0.99	0.17	ns
Executive Functioning: Trail Making Test			
Trail Making Part A Raw	31.60	22.86	ns
Trail Making Part A T Score	45.10	56.57	ns
Trail Making Part A Errors Score	0.33	0.40	ns
Trail Making Part B Raw	94.12	69.00	ns
Trail Making Part B T Score	40.20	51.14	ns
Trail Making Part B Errors Score	0.56	0.20	ns
Executive Functioning: Tower of London (TOL-2)			
London Drexel Total Move Raw	32.67	36.00	ns
London Drexel Total Move Standard Score	98.89	96.00	ns
London Drexel Total Correct Raw	3.78	4.00	ns
London Drexel Total Correct Standard Score	97.56	98.57	ns
London Drexel Total Rule Viol Raw Score	0.33	0.00	ns
London Drexel Total Rule Viol Standard Score	94.67	104.29	ns
London Drexel Total Time Viol Raw	0.89	0.86	ns
London Drexel Total Time Viol Standard Score	93.78	93.14	ns
London Drexel Total Initiation Time Raw	78.00	51.29	ns
London Drexel Total Initiation Standard Score	108.89	100.00	ns
London Drexel Total Execution Raw	220.22	207.86	ns
London Drexel Total Execution Standard Score	97.78	98.29	ns
London Drexel Total Prob Solv Raw	298.22	265.43	ns
London Drexel Total Prob Solv Standard Score	94.89	98.86	ns
Language: Controlled Oral Word Assoc. Test (COWAT)			
Control Oral Assoc Letter Fluency Raw	26.80	38.00	.043
Control Oral Assoc Letter Fluency T Score	34.10	46.71	.019
Control Oral Assoc Semantic Fluency Raw	16.20	18.14	ns
Control Oral Assoc Semantic Fluency T Score	34.80	45.00	ns
Premorbid Intellect: Test of Premorbid Functioning			
Premorbid Funct Raw	36.20	28.14	ns
Premorbid Funct T Score	93.80	86.57	ns
Visual Planning: Rey-Osterrieth Complex Figure Test			
Rey Osterrieth Raw	28.50	29.86	ns
Rey Osterrieth T Score	-0.49	-0.69	ns

Note: Significance tested using Mann-Whitney U tests; ns=non-significant

225

226 With regard to objective neuropsychological test measures, there were no statistically significant group

227 differences detected for premorbid functioning, learning and memory, attention, processing speed,

executive functioning, or visual planning. By contrast, the long COVID group scored significantly lower on

two measures of language related to letter fluency (raw score, 26.80 vs. 38.00, p=.043; T-Score 34.10 vs.

230 46.71, p=.019, Table 4).

It is made available under a CC-BY 4.0 International license .

# 231 Blood Biomarkers

- 232 Comparison of mean biomarker values between groups is presented in Table 5. The only significant
- 233 difference between groups was for serum NGF levels, which was significantly lower in the long COVID
- group (mean 9.72) compared to the control group (13.52, p= .038).
- 235

Table 5. Biomarkers	of Long COVID (	n=10) vs Controls (	(n = 7)	)
---------------------	-----------------	---------------------	---------	---

	Long COVID	Controls	
	mean*	mean	р
Cortisol Plasma	81.38	64.52	ns
Cortisol Serum	70.09	61.29	ns
DHEA-S Plasma	6058.83	1943.27	ns
DHEA-S Serum	3227.34	2773.22	ns
IL6 Plasma	1.25	1.29	ns
IL6 Serum	1.80	0.84	ns
IL10 Plasma	2.00	2.20	ns
IL10 Serum	4.45	2.96	ns
BDNF Plasma	897.45	779.73	ns
BDNF Serum	1502.62	1635.18	ns
NGF Plasma	27.24	25.98	ns
NGF Serum	9.72	13.52	.038
NfL Plasma	7.52	12.91	ns
NfL Serum	10.33	13.36	ns

Note: Significance tested using independent samples t tests and log-transformed biomarkers; ns=nonsignificant; DHEA-S = Dehydroepiandrosterone sulfate; IL=interleukin; BDNF=brain-derived neurotrophic factor; NGF=nerve growth factor; NfL=neurofilament light chain;\*units for cortisol and DHEA-S = ng/ml, all other biomarkers = pg/ml

236	When comparing groups based on biomarker scores below and above the median, the long COVID group
237	was significantly more likely than controls to have serum IL-10 values ≥ the median (p=0.015). Eight out
238	of ten participants in the long COVID group were classified into the $\geq$ median group vs 1 of 7 in the
239	control group. The increased inflammatory drive in long COVID patients was confirmed in terms of the
240	combined pro-inflammatory index, which included IL-6 as well as IL-10. Nine out of 10 patients in the
241	long COVID group exhibited serum pro-inflammatory index values ≥ the median compared to one out of
242	seven in the control group (Fisher's exact test, p = 0.042). For all other biomarkers, there were no
243	significant differences in terms of distribution of variables into below vs equal to and above the median.

It is made available under a CC-BY 4.0 International license .

#### 244

#### 245 Discussion

246	This exploratory pilot study compared two groups of laboratory-confirmed post-COVID patients at least
247	6 months after having been diagnosed with laboratory-confirmed COVID-19. One group was comprised
248	of individuals who had fully recovered (controls) and the other those continuing to experience cognitive
249	difficulties, referred to here as the long COVID group. To the best of our knowledge, this study of
250	cognitive symptoms was the first to use a study design where both the PCC (long COVID) and control
251	groups had a history of PCR-verified COVID-19 infection. Previous studies on cognitive impairment
252	defined healthy controls as individuals who had not had laboratory-confirmed COVID [7, 15, 25, 28]. In
253	an effort to understand why long COVID patients experience prolonged cognitive difficulties such as
254	brain fog, the current study aimed to examine and compare self-reported and objective measures in PCC
255	patients with cognitive complaints with fully recovered COVID patients. The overall study objective was
256	to inform the current understanding of neuropathophysiological disease mechanisms contributing to
257	non-recovery from COVID-19. Moreover, we were interested in findings that might inform the clinical
258	management of PCC.

259

260 From a cognitive standpoint, no significant differences were seen between the two groups as it 261 pertained to educational attainment or reading ability which is the most commonly used premorbid 262 estimate for neuropsychological purposes. Given comparable premorbid estimates, with the exception 263 of the letter fluency scores on the Controlled Oral Word Association Test (COWAT), this study found no 264 significant differences between groups in the neurocognitive test battery. This is in line with previous 265 research that found normal cognitive test results in adults with post-COVID cognitive symptoms [14, 16]. 266 By contrast, when dividing the PCC group into those with and without cognitive complaints, Ariza et al. 267 [15] found that those with cognitive complaints scored significantly worse on global cognition, learning,

It is made available under a CC-BY 4.0 International license .

memory, processing speed, language, and executive function. However, although our findings were
isolated to COWAT, this finding per se is novel since it has never been reported before, and the finding
supports PCC patients' self-reports of cognitive inefficiency and perhaps COVID fog. Specifically, this
task measures one's ability to engage in higher level thinking (a language task) under time constraint.
This could help to explain patients' reports of being able to cognitively engage but feeling that they are
foggy and that things take longer and do not seem as automatic.

274

275 More consistent group differences were found on self-report measures assessing functional status, 276 quality of life and mood. Specifically, the long COVID group in this study scored significantly and 277 consistently worse than controls on most validated self-report measures, indicating lower ratings on 278 quality of life, physical health, emotional functioning, and psychological well-being. Ariza et al. [15] also 279 reported lower quality of life and functioning scores among post-COVID patients compared to healthy 280 controls. However, unlike the present study that focused only on PCC patients with cognitive 281 complaints, the study by Ariza et al. [15] encompassed patients with a variety of post-COVID complaints. 282 Moreover, the control group in that study had not had a COVID-19 infection. By contrast, controls in the 283 current study were fully recovered COVID-19-infected patients who had not experienced any post-284 COVID symptoms.

285

With regard to blood biomarkers, the current study presents intriguing evidence in terms of decreased neuroplastic functioning in PCC patients vs the control group, as reflected in decreased serum levels of nerve growth factor (NGF). NGF is a neurotrophic protein that helps regulate neuronal and neurite growth [42] as well as neuronal phenotypic maintenance and immune function [43]. Brain plasticity and neuro-immunological functioning are closely related. Our findings suggest a sustained attenuation of brain neuroplastic activity. Such findings might contribute to the numerous patient-perceived reports of

It is made available under a CC-BY 4.0 International license .

292	attenuated neurocognitive functioning, although possibly not severe enough to be reflected in a
293	systematic decrease in objective neuropsychiatric test scores. Of note, self-rated health is a much better
294	predictor of future health and morbidity status than any clinical sign or laboratory test [44, 45]. It might
295	be that the body's internal sensor system is more sensitive and advanced than our current arsenal of
296	clinical and laboratory testing.
297	
298	However, when comparing groups based on biomarker scores below and above the median, the long
299	COVID group was significantly more likely than controls to have serum values ≥ the median for both IL-
300	10 alone as well as for the inflammatory index of IL-6 and IL-10 combined. Lai et al. [21] identified
301	interleukin (IL)-6 as a potential indicator of long COVID, while Queiroz et al. [22] found that patients with
302	no post-COVID symptoms had higher levels of IL-4, IL-6 and IL-10. However, neither of those studies
303	focused specifically on long COVID patients with cognitive complaints. Two studies that did study long
304	COVID patients with cognitive complaints found no cytokines or inflammatory markers associated with
305	cognitive performance [24,25]. Another common limitation in the above cited work is the lack of
306	objective verification of COVID-19 infection history. This limits the ability to determine whether findings
307	are related to COVID-19 infection history specifically or due to other possible confounders.
308	
309	When inflammatory marker scores were grouped above and below the median, a larger proportion of
310	long COVID patients fell into the $\geq$ median group for IL-10. IL-10 represents both a pro- and anti-
311	inflammatory marker [46]. In the current study, we used it as a pro-inflammatory marker. Prior research
312	has also suggested that IL-10 is related to self-reported energy [47]. In the latter case, our findings might
313	suggest a compensatory mechanism by which the body is trying to increase energy to counter the low
314	energy and high fatigue symptoms reported by a majority of long COVID patients. These findings of $\geq$

315 median levels of IL-6 and IL-10 support the hypothesis that there is residual activation of the

It is made available under a CC-BY 4.0 International license .

316 inflammatory systems in the long COVID group versus those that have recovered fully from PCR-verified 317 COVID-19. Looking at the proportion of participants falling into the high vs. low serum pro-inflammatory 318 group, all except one person in the long COVID group fell into the high serum pro-inflammatory group vs 319 one out of seven in the control group. Thus, overall, using several different definitions of pro-320 inflammation, the long COVID group systematically showed a pattern of heightened inflammation as 321 compared to the control group that has fully recovered from their COVID-19 infection. 322 323 Limitations 324 These results should be viewed in consideration of several study limitations. First and foremost is the 325 small sample size, which makes generalizability to other populations difficult, although we used a 326 rigorous assessment scheme. Small sample sizes have reduced statistical power to detect true effects 327 and results may be affected by outliers. However, we saw a consistent pattern of lower scores on all 328 self-rated health and quality of life measures, and higher depression and anxiety scores in the long-329 COVID group, which serves as validation for the group differences seen on biomarkers when examining 330 values above and below median scores. The study sample was not diverse, as participants were 331 primarily female and White. Notably, this was an exploratory pilot study that was, to the best of our

knowledge, unique in the comparison of COVID survivors with and without post-illness cognitive

333 symptoms. Thus, our control group had lab-verified histories of COVID infection from which they had

334 fully recovered.

335

336 Implications for clinical care

Results of this pilot study point to few but possibly clinically important differences between long COVID and control patients with regard to neurocognitive tests, but substantial differences related to physical and emotional functioning and quality of life. Although this was a small sample, results also suggest

It is made available under a CC-BY 4.0 International license .

possible prolonged inflammation in the long COVID group, which has been suggested previously [27], 340 341 however, without using a proper reference group. An interesting observation is the parallel between 342 this disorder and chronic fatigue syndrome (CFS), as both have patients reporting mood issues such as 343 anxiety [48]. This raises the question of what we can learn from the experience of patients with CFS and 344 whether that can be applied to long COVID patients with cognitive complaints. This may include 345 consideration of the types of clinical teams necessary to support the patients and their caregivers as well 346 as treatment. For example, there is no standard of care when it comes to treatment for CFS. Anhydrous 347 Enol-Oxaloacetate, (AEO) a nutritional supplement, has been anecdotally reported to relieve physical 348 and mental fatigue and is diminished in CFS patients [49]. Could this be a direction for us to consider for 349 guality-of-life outcomes for long COVID patients as well? Another factor to consider is the resources 350 needed to create longitudinal and multidisciplinary interventions that can support patients long-term -351 encompassing perceptions of quality of life, physical functioning, emotional health and wellbeing and 352 vocational rehabilitation - and the cost associated with such efforts. Combined exercise and behavioral 353 support, developed with extensive patient and stakeholder engagement, is being tested in a randomized 354 controlled trial in the United Kingdom [50]. Should it prove to be clinically cost-effective for people with 355 long-COVID, there is an opportunity to create similar programs.

356

In addition to the above, our results also support the importance of considering neuroinflammatory processes as treatment to this point has mostly focused on behavioral and cognitive interventions, assuming there are no residual neuro-inflammatory processes or deficits. This points to the importance of applying a multidisciplinary approach in addressing long COVID patients, including a rigorous assessment to detect possible residual systemic inflammation and reduced neuroplasticity. Such an approach could help to identify which patients may transition to experiencing long COVID and is likely to

It is made available under a CC-BY 4.0 International license .

- 363 expand the arsenal of choices of promising and evidence-based treatment strategies with the ultimate
- aim to design rigorous clinical trials.
- 365
- 366 Conclusions
- 367 Long COVID patients with cognitive complaints experience significantly more anxiety and depression,
- 368 lower self-rated health, and lower physical and emotional functioning and quality of life compared to
- 369 fully recovered COVID-19 patients, although only one neurocognitive test differed between groups.
- Biomarker analyses suggest possible prolonged inflammatory processes in long COVID patients.
- 371 Moreover, results of decreased neuroplastic functioning give credence to patients' reports of changes in
- brain function. Future studies in larger, more diverse samples are required to fully understand these
- 373 differences and to develop effective clinical treatments for those with cognitive difficulties.
- 374

# 375 Acknowledgements

- 376 The authors extend their gratitude to the patients who participated in the study and to John Beck, BS for
- 377 conducting the biomarker analysis. This study was financially supported by a grant from the Spectrum
- 378 Health Foundation (Grant nr. FDN 35911-2020-601).

379

388

391

# 380 References

- Hampshire A, Azor A, Atchison C, Trender W, Hellyer PJ, Giunchiglia V, et al. Cognition and memory after Covid-19 in a large community sample. N Engl J Med. 2024;390(9):806-818. doi: 10.1056/NEJMoa2311330.
- Scott A, Ansari W, Khan F, Chambers R, Benigno M, Di Fusco M, et al. Substantial health and
   economic burden of COVID-19 during the year after acute illness among US adults at high risk of
   severe COVID-19. BMC Med. 2024;22(1):46. doi: 10.1186/s12916-023-03234-6.
- Haider FH, Szczepek, AJ. Editorial: Neurotological consequences of long COVID. Front Neurol
   2022; 13:1087896. doi: 10.3389/fneur.2022.1087896. eCollection 2022.
- Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute
   COVID-19 syndrome. Nat Med 2021; 27(4):601-615. doi: 10.1038/s41591-021-01283-z.

394		
395	5.	Greenhalgh T, Sivan M, Perlowski A, Nicolich JZ. Long COVID: a clinical update. Lancet 2024;
396		404(10453):707-724. doi: 10.1016/S0140-6736(24)01136-X.
397		
398	6.	Perlis RH, Trujillo KL, Safarpour A, Santillana M, Ognyanova K, Druckman J, et al. JAMA Netw
399		Open 2024; 6(2):e2256152. doi: 10.1001/jamanetworkopen.2022.56152.
400		
401	7.	Jaywant A, Gunning FM, Oberlin FE, Santillana M, Ognyanova K, Druckman JN, et al. JAMA Netw
402		Open 2024; 7(2):e2356098. doi: 10.1001/jamanetworkopen.2023.56098.
403		
404	8.	Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Brain Behav Immun 2022; 101:93-135.
405		doi: 10.1016/j.bbi.2021.12.020.
406		
407	9.	Kao J, Frankland PW. Cell 2022; 185(14):2391-2393. doi: 10.1016/j.cell.2022.06.020.
408		
409	10.	Altuna M, Sanchez-Saudinos MB, Lleo A. Cognitive symptoms after COVID-19. Neurol Perspect
410		2021; S16-S24. doi: 10.1016/j.neurop.2021.10.005.
411		
412	11.	Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and
413		recommendations. Nat Rev Microbiol 2023; 21(3):133-146. doi: 10.1038/s41579-022-00846-2.
414		
415	12.	Hellmuth J, Barnett TA, Asken BM, Kelly JD, Torres L, Stephens ML, et al. Persistent COVID-19-
416		associated neurocognitive symptoms in non-hospitalized patients. J Neurovirol 2021; 27(1):191-
417		195. doi: 10.1007/s13365-021-00954-4.
418		
419	13.	Liu TC, Yoo SM, Sim MS, Motwani Y, Viswanathan M, Wenger NS. Perceived cognitive deficits in
420		patients with symptomatic SARS-CoV-2 and their association with post–COVID-19 condition.
421		JAMA Netw Open 2023; 6(5):e2311974. doi: 10.1001/jamanetworkopen.2023.11974.
422		Development of the second s
423	14.	Rennison VLA, Chovaz CJ, Zirui S. Cognition and psychological well-being in adults with post
424		COVID-19 condition and analyses of symptom sequelae. Clin Neuropsychol 2024; 38(2):326-353.
425		001: 10.1080/13854046.2023.2227407.
426	4 -	Arias M. Carra N. Castura D. Daine I. Dannie C. NAUTULIC Drainet Callaboration Crasura at al
427	15.	Ariza Mi, Cano N, Segura B, Bejar J, Barrue C, NAUTILUS Project Collaborative Group, et al.
428		Transl Neural 2024: 11(2):202-220. doi: 10.1002/com2.51052
429		ITALISI NEUTOI 2024; 11(2):302-320. 001. 10.1002/dcl13.51952.
450	16	Whiteside DM Rasso MR Naini SM Portor L Holker E Waldren EL et al Outsemes in post
451	10.	acute sequelae of COVID 10 (DASC) at 6 months post infection Dart 1: Cognitive functioning. Clin
432		Neuropsychol 2022: 26(4):206-222 doi: 10.1020/12254046.2022.2020412
433		Neuropsychol 2022, 30(4).800-828. dol. 10.1080/13834040.2022.2030412.
734 125	17	Rattaglini D. Lones-Pacheco M. Castro-Faria-Neto HC. Pelosi P. Posco PPM. Laboratory
136 //36	т/.	hiomarkers for diagnosis and prognosis in COVID-19 Front Immunol 2022: 12:857572 doi:
430		10 2280/fimmu 2022 857573
/28		10.3303/11111110.2022.037373.
430	18	Conti V. Corhi G. Sabbatino F. De Pascale D. Sellitto C. Stefanelli R. et al. Long COVID: clinical
440	10.	framing, biomarkers, and therapeutic approaches. J Pers Med 2023: 13(2):334 doi:

441 442	10.3390/jpm13020334.
443 1 444 445	<ol> <li>Espin E, Yang C, Shannon CP, Assadian S, He D, Tebbutt SJ. Cellular and molecular biomarkers of long COVID: a scoping review. EBioMedicine 2023; 91:104552. doi: 10.1016/j.ebiom.2023.104552.</li> </ol>
446	
447 2 448 449	<ul> <li>M. Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19         <ul> <li>A systematic review. Life Sciences 2020; 254:117788. doi.org/10.1016/j.lfs.2020.117788.</li> </ul> </li> </ul>
450 2 451 452 453	<ol> <li>Lai Y-J, Liu S-H, Manachevakul S, Lee T-A, Kuo C-T, Bello D. Biomarkers in Long COVID-19: a systematic review. Front Med (Lausanne) 2023; 10:1085988. doi: 10.3389/fmed.2023.1085988. eCollection 2023.</li> </ol>
454 2 455 456 457	<ol> <li>Queiroz MAF, Moura das Neves PF, Lima SS, da Costa Lopes J, da Silva Torres MK, Vallinoto IMVC, et al. Cytokine profiles associated with acute COVID-19 and Long COVID-19 Syndrome. Front Cell Infect Microbiol 2022; 12:922422. doi: 10.3389/fcimb.2022.922422. eCollection 2022.</li> </ol>
458 2 459 460 461	<ol> <li>Tsilingiris D, Vallianou NG, Karampela I, Christodoulatus GS, Papavasileiou G, et al. Laboratory findings and biomarkers in long COVID: what do we know so far? Insights into epidemiology, pathogenesis, therapeutic perspectives and challenges. Int J Mol Sci 2023; 24(13):10458. doi: 10.3390/ijms241310458.</li> </ol>
462 463 2 464 465 466 467	<ol> <li>Damiano RF, de Almeida Rocco CC, de Padua Serafim A, Loftis JM, Talib LL, Petropoulou D, et al. Cognitive impairment in long-COVID and its association with persistent dysregulation in inflammatory markers. Front Immunol 2023; 14:1174020. doi: 10.3389/fimmu.2023.1174020. eCollection 2023.</li> </ol>
467 468 2 469 470 471	<ol> <li>Vrettou CS, Vassiliou AG, Keskinidou C, Mourelatos P, Asimakos A, Spetsioti S, et al. A prospective study on neural biomarkers in patients with long-COVID symptoms. J Pers Med 2024; 14(3):313. doi: 10.3390/jpm14030313.</li> </ol>
471 472 2 473 474 475	<ol> <li>Frontera JA, Simon NM. Bridging knowledge gaps in the diagnosis and management of neuropsychiatric sequelae of COVID-19. JAMA Psychiatry 2022; 79(8):811-817. doi: 10.1001/jamapsychiatry.2022.1616.</li> </ol>
476 2 477 478 479	<ol> <li>Lamontagne SJ, Winters MF, Pizzagalli DA, Olmstead MC. Post-acute sequelae of COVID-19: evidence of mood and cognitive impairment. Brain Behav Immun Health 2021; 17:100347. doi: 10.1016/j.bbih.2021.100347.</li> </ol>
480 2 481 482 483	<ol> <li>Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 "long haulers." Ann Clin Transl Neurol 2021; 8(5):1073-1085. doi: 10.1002/acn3.51350.</li> </ol>
484 2 485 486	<ol> <li>Beck AT, Steer RA, Brown G. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation, 1996.</li> </ol>

487 3 488	<ol> <li>Beck A, Steer R. Beck Anxiety Inventory manual. San Antonio, TX: Psychological Corporation: 1993.</li> </ol>
489	
490 :	1. Ware, J., Sherbourne, C. The MOS 36-Item Short-Form Health Survey (SF-36): conceptual
491	framework and item selection. Med Care 1992; 30(6): 473-83.
492	
493 3	2. McHorney CA, Ware JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-
494	36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups.
495	Med Care 1994; 32(1): 40-66. doi: 10.1097/00005650-199401000-00004.
496	
497 3	3. The EuroQol Group. EuroQol - a new facility for the measurement of health related quality of
498	life. Health Policy 1990; 16(3), 199-208. doi: 10.1016/0168-8510(90)90421-9.
499	
500	4. Wechsler, D. The test of premorbid function (TOPF). San Antonio, TX: The Psychological
501	Corporation, 2011.
502	
503 3	5. Wechsler, D. Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Technical and
504	Interpretive Manual. San Antonio, TX: Pearson, 2008.
505	, , , , , , , , , , , , , , , , , , ,
506 3	6. Smith, A. Symbol Digits Modalities Test: Manual, Los Angeles Western Psychological Services.
507	2007.
508	
509 3	7 Benton AL Spreen O Hamsher KD Contributions to Neuropsychological Assessment: A Clinical
510	Manual 2nd ed New York NY: Oxford University Press 1983
510	
512 3	8 Meyers I. Meyers K. Rey complex figure test and recognition trial: Professional manual PAR
512	Inc. 1005
513	IIIC, 1995.
514	20 Delis DC Kramer IH Kaplan E. Ober PA. California Verbal Learning Test. and ed. San Antonio. TX:
515 5	B. Dens DC, Kramer JH, Kapian E, Ober BA. Camornia verbai Learning Test. 2nd ed. San Antonio, TX.
510	
517	0 Deitan D. Walfson D. The Halstood Deitan Neuropsychological Test Pattery, Theory 9
518 4	U. Reitan, R., Wollson, D. The Haistead-Reitan Neuropsychological Test Battery: Theory &
519	Interpretation. Tucson, AZ: Neuropsychology Press, 1985.
520	
521 4	1. Culbertson, W., Zillmer, E. Tower of London – Drexel University. Znd ed. Canada: Multi-Health
522	Systems Inc, 2005.
523	
524 4	2. Levi-Montalcini R, Dal Toso R, della Valle F, Skaper SD, Leon A. Update of the NGF saga. J Neurol
525	Sci 1995; 130(2):119-27. doi: 10.1016/0022-510x(95)00007-o.
526	· · · · · · · · · · · · · · · · · · ·
527 4	3. Minnone G, De Benedetti F, Bracci-Lauderio L. NGF and its receptors in the regulation of
528	inflammatory response. Int J Mol Sci 2017; 18(5):1028. doi: 10.3390/ijms18051028.
529	
530 4	4. Halford C, Anderzen I, Arnetz B. Endocrine measures of stress and self-rated health: a
531	longitudinal study. J Psychosom Res 2003; 55(4):317-20. doi: 10.1016/s0022-3999(02)00634-7.
532	
533 4	5. Halford C, Ekselius L, Anderzen I, Arnetz B, Svärdsudd K. Self-rated health, life-style, and
534	psychoendocrine measures of stress in healthy adult women. Ups J Med Sci 2010; 115(4):266-

It is made available under a CC-BY 4.0 International license .

	74. doi: 10.3109/03009734.2010.496910.
46.	Keaton SA, Arnetz J, Jamil H, Dhalimi A, Stemmer PM, Ruden DM, et al. IL-10: a possible immunological component of positive mental health in refugees. Compre Psychoneuroendocrinol 2021; 8:100097. doi: 10.1016/j.cpnec.2021.100097.
47.	Keaton S, Krzyzanowski S, Arnetz J, Hikmet J, Dhalimi A, Stemmer P, et al. IL-10 is associated with increased energy in newly arrived traumatized Middle Eastern refugees in the US. Biol Psychiatry 2017; 81:S140–S276. www.sobp.org/journal.
48.	Azcue N, Gomez-Esteban JC, Acera M, Tijero B, Fernandez T, Ayo-Mentxakatorre N, et al. Brain fog of post-COVID-19-condition and Chronic Fatigue Syndrome, same medical disorder? J Transl Med 2022; 20(1):569. doi: 10.1186/s12967-022-03764-2.
49.	Cash A, Kaufman DL. Oxaloacetate treatment for mental and physical fatigue in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non- randomized controlled clinical trial. J Transl Med 2022; 20(1):295. doi: 10.1186/s12967-022- 03488-3.
50.	Ennis S, Heine P, Sandhu H, Sheehan B, Yeung J, McWilliams, D, et al. Development of an online intervention for the rehabilitation exercise and psychological support after covid-19 Infection (REGAIN) trial. NIHR Open Res 2023; 3:10. doi: 10.3310/nihropenres.13371.2. eCollection 2023.
Suppor	ting Information
S1 Data	aset (XLSX)
	46. 47. 48. 49. 50. <b>Suppor</b> S1 Data